<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551042</url>
  </required_header>
  <id_info>
    <org_study_id>13/0417</org_study_id>
    <secondary_id>2014-001101-40</secondary_id>
    <nct_id>NCT02551042</nct_id>
  </id_info>
  <brief_title>CSL Behring Sclero XIII</brief_title>
  <official_title>A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels,
      mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers
      or toes turning white then blue in the cold) and digital ulcers (open sores on the
      fingertips). The purpose of this study is to see how effective the study drug Human Factor
      XIII Concentrate is in treating patients who have these and other common manifestation of
      Scleroderma. It will be given in addition to the accepted treatments used for this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, double-blind, randomized, placebo-controlled study to investigate
      pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients
      with systemic sclerosis.

      Scleroderma (Systemic sclerosis) is a multisystem rheumatic disease that is characterised by
      progressive vascular damage e.g Raynaud's phenomenon and digital ulcers and organ fibrosis
      e.g. skin thickening and pulmonary fibrosis.The disease is associated with significant
      morbidity and mortality and current therapeutic options are only partially effective,
      including Cyclophosphamide for skin or lung fibrosis and Bosentan which reduces but does not
      heal digital ulcers.

      There is no cure available and there is therefore a high need for new therapeutic
      options.Administration of human Factor XIII (FXIII) concentrate in patients with scleroderma
      demonstrated promising results in the 1980s and 1990s . However these studies were not
      performed according to current Good Clinical Practice (GCP) guidelines and involved
      relatively small sample sizes.

      This is a single site study, therefore all study participants will be seen at the Royal Free
      London National Health Service (NHS) Foundation Trust.Total study duration is 36 months and
      will involve 2 phases: an initial single dose, pharmacokinetic (PK) phase in 8 subjects over
      6 weeks and a multiple dose, active treatment phase in 18 subjects over 24 weeks. During the
      treatment phase subjects will be randomized at 2:1 ratio to either FXIII or Placebo and will
      receive biweekly injection of either factor XIII Concentrate or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome assessed by skin involvement measured with modified Rodnan skin score</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary outcome assessed by skin involvement measured with Raynaud condition score</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measured by pulmonary function test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pulmonary function measured by pulmonary function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand function measured with Cochin hand function</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hand function measured with Cochin hand function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with Short Form-36 (SF-36) quality of life questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of life measured with SF36 quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new digital ulcers (DU)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Prevention of new DU: Number of new DU developed during a 24-week period of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete healing of digital ulcers (DU)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Healing of DU: Complete healing of DUs present at baseline; each DU is considered as an entity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer pain assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>DU Pain assessment at 4, 8, 12, 16, 24 weeks of treatment: Pain will be assessed by analogue scale for pain (Visual Analogue Scale, VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer pain assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>DU Pain assessment at 4, 8, 12, 16, 24 weeks of treatment: Pain will be assessed by Raynaud's severity (Raynaud's condition score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: hospitalisation required</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of overnight hospitalisations for digital ulcers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: surgical intervention required</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of additional surgical treatments for digital ulcer in outpatient clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Digital ulcer infection</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of digital ulcers with infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Gangrene</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of episodes of gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Amputation</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Need of local sympathectomy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of local sympathectomies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Need of toxin Botulinum A</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of treatments with Botulinum toxin A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Need of oral or parenteral antibiotic</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of treatments needed with oral or parenteral antibiotic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital ulcer worsening: Need of intravenous (IV) Iloprost : this is considered treatment failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of treatments needed with intravenous (IV) Iloprost : this is considered treatment failure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints: Physical examination (including height, weight, BMI, digital ulcer characterization)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Physical examination (including height, weight, BMI, digital ulcer characterization)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Serious adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: ECG</measure>
    <time_frame>24 weeks</time_frame>
    <description>ECG</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Vital signs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Vital signs</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Clinical laboratory parameters</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical laboratory parameters</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Pregnancy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Serum or urine pregnancy tests will be performed at each visit and will be reported positive or negative</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints -Adverse events of special interest: thromboembolic events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events of special interest: thromboembolic events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be 0.9 % Sodium chloride solution IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrogammin®P, coagulation factor XIII concentrate (Human)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Active treatment arm</arm_group_label>
    <other_name>Factor XIII</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults.

          -  Subjects with a diagnosis of systemic sclerosis (scleroderma, SSc) according to the
             2013 American College of Rheumatology European League Against Rheumatism (ACR EULAR)
             classification criteria. They will be classified according to LeRoy criteria as
             limited or diffuse subset.

          -  Females of childbearing potential must be willing to use a reliable form of medically
             acceptable contraception and have a negative pregnancy test.

          -  Subjects will have serological status for hepatitis A and B assessed at screening.

          -  Patients who have given their free and informed consent. -≥ 18 years.

        Exclusion Criteria:

        Participants must:

          -  Be willing to use an effective method of contraception (hormonal or barrier method of
             birth control; abstinence) from the time consent is signed until 6 weeks after
             treatment discontinuation (females of childbearing potential and males)

          -  Have a negative pregnancy test within 7 days prior to being registered for trial
             treatment (females of childbearing potential). NOTE: Subjects are considered not of
             child bearing potential if they are surgically sterile (i.e. they have undergone a
             hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
             postmenopausal.

          -  Not be breastfeeding (females).

        Participants must not:

          -  Have allergies to excipients of the investigational medicinal product (IMP) and
             placebo

          -  Have uncontrolled systemic hypertension as evidenced by sitting systolic blood
             pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg.

          -  Have portal hypertension or chronic liver disease defined as mild to severe hepatic
             impairment (Child-Pugh Class A-C). Subjects positive for Hepatitis C with evidence of
             active viral replication on sensitive polymerase chain reaction (PCR) testing are also
             excluded.

          -  Have hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or alanine
             aminotransferase (ALT) ≥ 3 times the upper limit of the normal range (× ULN) at the
             Screening Visit.

          -  Have chronic renal insufficiency as defined by a serum creatinine ≥ 2.5 mg/dL (≤ 221
             micromol/L) or requires dialysis.

          -  Have a haemoglobin concentration ≤ 10 g/dL (≤ 100 g/L) at the Screening Visit.

          -  Have a history of left-sided heart disease and/or clinically significant cardiac
             disease, including but not limited to any of the following: aortic or mitral valve
             disease (stenosis or regurgitation) defined as more than minimum aortic insufficiency
             and more than moderate mitral regurgitation (stenosis or regurgitation≥ grade 1);
             pericardial constriction; restrictive or congestive cardiomyopathy; left ventricular
             ejection fraction ≤ 40 % by multiple gated acquisition scan (MUGA), angiography, or
             echocardiography; left ventricular shortening fraction ≤ 22 % by echocardiography; or
             symptomatic coronary disease with demonstrable ischemia.

          -  Have a history of malignancies within 5 years of Screening Visit with the exception of
             localized skin or cervical carcinomas.

          -  Have psychiatric, addictive, or other disorder that compromises the ability to give
             informed consent for participating in this study. This includes subjects with a recent
             history of abusing alcohol or illicit drugs.

          -  Be receiving ongoing treatment with hyperbaric oxygen

          -  Have pulmonary artery hypertension (PAH)

          -  Have received IV Iloprost within the last 2 months

          -  Have been treated with sympathectomy or toxin botulinum A within the last 3 months

          -  Have had thrombosis, stroke, pulmonary embolism or myocardial infarction in the last 6
             months

          -  Have a diagnosis of diabetes mellitus requiring dietary restriction of carbohydrate.

          -  Be on a low sodium diet on medical advice.

          -  Be participating in another clinical trial involving an investigational medicinal
             product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Denton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free London NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Denton, PhD</last_name>
    <phone>02073177544</phone>
    <email>c.denton@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Ochiel</last_name>
    <phone>02073177544</phone>
    <email>rachel.ochiel@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://ec.europa.eu/health/documents/community-register/2012/20120903123586/anx_123586_en.pdf</url>
    <description>NovoThirteen® Summary of Product Characteristics</description>
  </link>
  <reference>
    <citation>LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202-5.</citation>
    <PMID>3361530</PMID>
  </reference>
  <reference>
    <citation>Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2008 Jan;67(1):120-3. Epub 2007 Jul 27.</citation>
    <PMID>17660220</PMID>
  </reference>
  <reference>
    <citation>Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion. 2013 May;53(5):1120-31. doi: 10.1111/j.1537-2995.2012.03865.x. Epub 2012 Aug 28. Review.</citation>
    <PMID>22928875</PMID>
  </reference>
  <reference>
    <citation>Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7296-300.</citation>
    <PMID>7913750</PMID>
  </reference>
  <reference>
    <citation>Nugent DJ. Prophylaxis in rare coagulation disorders -- factor XIII deficiency. Thromb Res. 2006;118 Suppl 1:S23-8. Epub 2006 Apr 17. Review.</citation>
    <PMID>16616323</PMID>
  </reference>
  <reference>
    <citation>Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RA, Seifried E, Oldenburg J; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost. 2007 Jun;97(6):914-21.</citation>
    <PMID>17549292</PMID>
  </reference>
  <reference>
    <citation>Dallabrida SM, Falls LA, Farrell DH. Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin. Blood. 2000 Apr 15;95(8):2586-92.</citation>
    <PMID>10753838</PMID>
  </reference>
  <reference>
    <citation>Dardik R, Shenkman B, Tamarin I, Eskaraev R, Harsfalvi J, Varon D, Inbal A. Factor XIII mediates adhesion of platelets to endothelial cells through alpha(v)beta(3) and glycoprotein IIb/IIIa integrins. Thromb Res. 2002 Feb 15;105(4):317-23.</citation>
    <PMID>12031826</PMID>
  </reference>
  <reference>
    <citation>Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A, Goldberg I, Schiby G, Inbal A. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1472-7. Epub 2003 Jun 12.</citation>
    <PMID>12805075</PMID>
  </reference>
  <reference>
    <citation>Dardik R, Leor J, Skutelsky E, Castel D, Holbova R, Schiby G, Shaish A, Dickneite G, Loscalzo J, Inbal A. Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. Thromb Haemost. 2006 Mar;95(3):546-50.</citation>
    <PMID>16525585</PMID>
  </reference>
  <reference>
    <citation>Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis. 2006 Oct;65(10):1325-9. Epub 2006 Mar 15.</citation>
    <PMID>16540546</PMID>
  </reference>
  <reference>
    <citation>Kilian O, Fuhrmann R, Alt V, Noll T, Coskun S, Dingeldein E, Schnettler R, Franke RP. Plasma transglutaminase factor XIII induces microvessel ingrowth into biodegradable hydroxyapatite implants in rats. Biomaterials. 2005 May;26(14):1819-27.</citation>
    <PMID>15576156</PMID>
  </reference>
  <reference>
    <citation>Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets. 2008 Oct;9(10):851-62. Review.</citation>
    <PMID>18855619</PMID>
  </reference>
  <reference>
    <citation>Nör JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res. 2000 May-Jun;37(3):209-18.</citation>
    <PMID>10859480</PMID>
  </reference>
  <reference>
    <citation>Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, Janes L, Lange-Asschenfeldt B, Yano K, Hawighorst T, Iruela-Arispe L, Detmar M. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 2000 Jul 3;19(13):3272-82.</citation>
    <PMID>10880440</PMID>
  </reference>
  <reference>
    <citation>Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):526-32. Epub 2004 Dec 23.</citation>
    <PMID>15618543</PMID>
  </reference>
  <reference>
    <citation>Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost. 2006 Jan;4(1):19-25. Epub 2005 Aug 26.</citation>
    <PMID>16129024</PMID>
  </reference>
  <reference>
    <citation>Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. Review.</citation>
    <PMID>19420368</PMID>
  </reference>
  <reference>
    <citation>Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM, Goldblum SE. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol. 2002 Dec;29(12):2565-70.</citation>
    <PMID>12465153</PMID>
  </reference>
  <reference>
    <citation>Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol. 2005 May;166(5):1451-63.</citation>
    <PMID>15855645</PMID>
  </reference>
  <reference>
    <citation>Avouac J, Clemessy M, Distler JH, Gasc JM, Ruiz B, Vacher-Lavenu MC, Wipff J, Kahan A, Boileau C, Corvol P, Allanore Y. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. Rheumatology (Oxford). 2011 Aug;50(8):1494-504. doi: 10.1093/rheumatology/keq448. Epub 2011 Mar 30.</citation>
    <PMID>21454305</PMID>
  </reference>
  <reference>
    <citation>Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010 Feb;62(2):580-8. doi: 10.1002/art.27220.</citation>
    <PMID>20112379</PMID>
  </reference>
  <reference>
    <citation>Paye M, Nusgens BV, Lapière CM. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasis. 1989;19(5):274-83.</citation>
    <PMID>2777140</PMID>
  </reference>
  <reference>
    <citation>Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem. 2003 Jul 4;278(27):25109-19. Epub 2003 Apr 21.</citation>
    <PMID>12707256</PMID>
  </reference>
  <reference>
    <citation>Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998 Jun 26;93(7):1159-70.</citation>
    <PMID>9657149</PMID>
  </reference>
  <reference>
    <citation>Thivolet J, Perrot H, Meunier F, Bouchet B. [Therapeutic action of coagulation factor XIII in scleroderma. 20 cases]. Nouv Presse Med. 1975 Nov 15;4(39):2779-82. French.</citation>
    <PMID>1105424</PMID>
  </reference>
  <reference>
    <citation>Delbarre F, Godeau P, Thivolet J. Factor XIII treatment for scleroderma. Lancet. 1981 Jul 25;2(8239):204.</citation>
    <PMID>6114269</PMID>
  </reference>
  <reference>
    <citation>Guillevin L, Chouvet B, Mery C, Thivolet J, Godeau P, Delbarre F. [Treatment of generalized scleroderma with factor XIII. Study of 25 cases]. Rev Med Interne. 1982;3(3):273-7. French.</citation>
    <PMID>6758093</PMID>
  </reference>
  <reference>
    <citation>Guillevin L, Euller-Ziegler L, Chouvet B, De Gery A, Chassoux G, Lafay P, Ziegler G, Godeau P, Amor B, Thivolet J. [Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up]. Presse Med. 1985 Dec 28;14(46):2327-9. French.</citation>
    <PMID>2935830</PMID>
  </reference>
  <reference>
    <citation>Euller-Ziegler L, Corolleur YR, Marcou J, Commandre F, Grisot C, Ziegler G. [Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function]. Rev Rhum Mal Osteoartic. 1984 Oct;51(9):503-5. French.</citation>
    <PMID>6505601</PMID>
  </reference>
  <reference>
    <citation>Maekawa Y, Nogita T, Yamada M. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis. Arch Dermatol. 1987 Nov;123(11):1440-1.</citation>
    <PMID>3674907</PMID>
  </reference>
  <reference>
    <citation>Guillevin L, Chouvet B, Mery C, De Gery A, Thivolet J, Godeau P, Delbarre F. Treatment of progressive systemic sclerosis using factor XIII. Pharmatherapeutica. 1985;4(2):76-80.</citation>
    <PMID>3903781</PMID>
  </reference>
  <reference>
    <citation>Quillinan NP, McIntosh D, Vernes J, Haq S, Denton CP. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis. 2014 Jan;73(1):56-61. doi: 10.1136/annrheumdis-2013-203674. Epub 2013 Sep 25.</citation>
    <PMID>24067785</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digital Ulcers</keyword>
  <keyword>Raynauds Phenomenon</keyword>
  <keyword>Factor XIII</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

